Transthyretin Amyloidosis Clinical Trials in Boston, Massachusetts
6 recruitingBoston, Massachusetts
Showing 1–6 of 6 trials
Recruiting
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals2,000 enrolled4 locationsNCT07358078
Recruiting
Phase 3
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals1,250 enrolled207 locationsNCT07052903
Recruiting
Phase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
CardiomyopathiesAmyloidosisHeart Diseases+3 more
Eidos Therapeutics, a BridgeBio company582 enrolled98 locationsNCT06563895
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Transthyretin AmyloidosisATTR-CMATTRv-PN+3 more
AstraZeneca1,850 enrolled53 locationsNCT06465810
Recruiting
Phase 3
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Intellia Therapeutics1,200 enrolled132 locationsNCT06128629
Recruiting
Not Applicable
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Heart FailureAmyloidosisHeart Failure, Diastolic+1 more
Massachusetts General Hospital515 enrolled1 locationNCT05577819